The Sertraline Antidepressant Heart Attack Randomized Trial found that patients with acute coronary syndrome and comorbid depression exhibited greater levels of platelet factor 4, platelet endothelial cell adhesion molecule-1, and thromboxane, which suggests enhanced platelet activation and aggregation. Here, PECAM1 is linked to major depressive disorder.